Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Urinary Biomarker Study of Polyamine Inhibition With Sulindac and Difluoromethylornithine (DFMO)

NCT01636128 is registered in ClinicalTrials.gov with Cancer Prevention Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01636128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01636128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Urinary Biomarker Study of Polyamine Inhibition With Sulindac and Difluoromethylornithine (DFMO)
Lead sponsor
Cancer Prevention Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
March 31, 2014
Completion date
April 30, 2016
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

focus of study: drug response biomarkers, chemoprevention, neoplasms